Re: W8 X64 X86 Aio En-us Activator
Alfonzo Liebenstein
Get gorgeous curls any day of the week with Aussie Miracle Curls 2nd Day Curl Activator. This little miracle worker is packed with moisturizing ingredients like jojoba oil and coconut. It works to refresh and revive your curls and keep them frizz-free while the Aussie Miracle Curls Refresher Spray Gel works to hold your curls in place.
It's so hard to find good products for natural hair. Especially curl activators but Aussie never disappoints! This product helps bring my curls back to life days after wash day. It smells amazing and moisturizes your hair. You can't go wrong.
This AU 2nd Day Curl Activator 12 8.5 oz is so amazing! First of all, it smells so fabulous I could spray it on my hair all day long. Second, it works so wonderfully on my hair and on my daughter's hair which is even curlier and frizzier than mine. I love how it curls and defines my hair. This is my new favorite curl activator and will be using it every day from now on I just love it! I highly recommend this product.
Strong activation is essential for success in all PLC settings. We will face many challenges and ups and downs through the course of the upcoming or current school year. The role of the activator is critical to the success of the PLC by moving forward the learning of both the adults and our students. Many previous PLC models and frameworks have disregarded the role human behavior plays when it comes to collaborative efforts to impact student learning at high levels. The activator has the ability to move a PLC from chaos and dysfunction into impactful action, from where team members are stagnant to where they are thriving. With all of the distractions that will compete for our attention, the activator ensures that we are focused on the learning and development of both adults and the students we teach. Whether in a classroom or from our couch, the laboratory or the living room, activators arm help us overcome any challenges we may face.
These six characteristics are designed to capitalize on the professionalism of teaching. As experts in not just what to teach, but how to teach, the work of PLCs must move beyond using this much needed to time to vent. Furthermore, we cannot avoid having critical and difficult conversations or addressing complex problems for fear of adding to the stress that might accompany the upcoming or current academic year. In fact, the work of our PLCs reduces the cognitive load by leveraging the collective expertise of the PLC. In other words, we are not going at this alone.
Corwin has one mission: to enhance education through intentional professional learning. We build long-term relationships with our authors, educators, clients, and associations who partner with us to develop and continuously improve the best, evidence-based practices that establish and support lifelong learning.
A stroke occurs when the blood supply to brain tissue is blocked by a blood clot (ischemic stroke), or when a blood vessel in the brain ruptures (hemorrhagic stroke), causing brain cells to die and leading to functional impairments. Stroke is a leading cause of death and disability both globally and in the U.S., where approximately 800,000 people experience a stroke each year1.
Although stroke remains a critical health issue, better management of cardiovascular risk factors, greater awareness of symptoms, and prompt medical attention are helping to prevent strokes and improve outcomes. Accordingly, the death rate from stroke in the U.S. fell 77% between 1969 and 20132. Another major advance was the clot-dissolving medicine tPA (for tissue plasminogen activator), the first treatment for acute ischemic stroke to receive Food and Drug Administration (FDA) approval. Known by the generic name alteplase and marketed as Activase (Genentech), tPA is given to patients through an IV in the arm, and it works by dissolving blood clots that block blood flow to the brain. When administered quickly after stroke onset (within three hours, as approved by the FDA), tPA helps to restore blood flow to brain regions affected by a stroke, thereby limiting the risk of damage and functional impairment.
Beginning in the 1950s, investigators first began to develop clot-dissolving, or thrombolytic, interventions for heart attacks and stroke. Early agents included the bacterial enzyme streptokinase and urokinase, an enzyme produced in the kidneys. However, both carried significant risks for dangerous internal bleeding, or hemorrhage, as they prevented clotting throughout the body.3 While tPA had also been discovered by this time,4 it was not extensively studied until the late 1970s, following a fortuitous finding that certain cancer cells grown in the lab produced large amounts of the enzyme.5 This allowed more thorough characterization, which showed that tPA acted preferentially at clots, a potentially major advantage over previously tested enzymes.6
The first studies demonstrating the clot-busting effects of tPA were conducted in the early 1980s, in animal models of coronary artery and other blockages and in a small number of heart attack patients,7 though not yet in stroke patients. The 1980s also ushered in a revolution in biotechnology. Scientists could now clone genes and directly express proteins in cell cultures, and Genentech researchers began producing recombinant tPA in sufficient quantities for future commercialization.8 In 1984, the National Heart, Lung, and Blood Institute (NHLBI) supported the first multicenter, randomized clinical trial using recombinant tPA in heart attack patients. This trial showed successful coronary artery opening in 75% of patients with limited adverse bleeding.9 Based on positive results in additional trials,10,11 the FDA approved tPA (alteplase, Activase) for treating heart attack12 in 1987.
Meanwhile, NINDS researchers and others thought tPA might be used to treat stroke as well. Earlier failures with streptokinase and urokinase had discouraged further investigation of thrombolytic agents for stroke. However, researchers now understood that these trials had begun treatment too late to salvage oxygen-deprived brain tissue. Furthermore, since tPA carried less risk of internal bleeding, it could be given intravenously, as opposed to directly to an affected artery, a process that required additional time-consuming examination. By the late 1980s, several studies supported in part by NINDS had found that intravenous tPA could dissolve clots in animal models with limited risk of hemorrhage, but only if tPA was administered shortly after the clot blocked blood flow.13,14,15,16,17,18
In the early 1990s, reports of pilot trials of tPA in small numbers of stroke patients described artery opening and improved outcomes.19,20 In particular, two studies involving NINDS support and NINDS intramural investigators developed protocols for assessing and treating stroke patients within 90 minutes or less and three hours or less of symptom onset, based on earlier evidence of the window of opportunity to prevent irreversible damage.21,22 These pioneering studies radically increased the speed with which stroke patients could be diagnosed and treated. They also established that the effective dose of tPA for stroke was less than the standard dose for heart attack, further decreasing the risk for dangerous bleeding. Larger randomized, placebo-controlled studies followed,23,24 including the NINDS tPA Stroke Trial.25 In 1995, results from this pivotal trial showed that patients treated with tPA within three hours of symptom onset were at least 30 percent more likely than placebo-treated patients to have minimal or no disability for up to three months. Treatment with tPA was associated with a greater risk of bleeding in the brain, especially in patients with severe strokes. However, tPA treatment in such patients was still more likely than placebo to result in better outcomes, and mortality did not increase overall in tPA-treated patients.
Thanks in large part to the NINDS-supported trial, the FDA approved tPA26 for the treatment of ischemic stroke in 1996. Follow-up studies confirmed that tPA treatment outcomes observed in the NINDS trial persisted for up to one year,27 and postmarketing studies showed that community hospitals could achieve similar results with adherence to recommended protocols for rapid assessment and treatment.28 In addition, a study on cost benefits estimated $4 million in savings for every 1,000 patients treated with tPA, due to improved outcomes and reduced long term care costs.29
NINDS and others have continued to support efforts to increase the use of tPA in eligible patients and improve treatment outcomes, including research on ways to mitigate the risk of bleeding in the brain and extend the time window for treatment. Moreover, the success of tPA motivated the search for additional acute stroke treatments, including interventions to remove large clots resistant to the clot-busting drug. In 2015, multiple clinical trials demonstrated the benefit of clot-retrieval devices as compared to tPA alone for the treatment of severe strokes affecting large arteries to the brain,31 prompting the FDA to expand approval for such devices32. Subsequent clinical trials sponsored by industry and NINDS showed that the time window for effective treatment with these devices can be extended to 16 hours or more in patients determined by brain imaging to have salvageable brain tissue.33,34.
LOCTITE SF 7649 is specially designed to promote the cure speed of LOCTITE anaerobic adhesives and sealants without any significant loss of joint strength. Ideal for applications with passive metals or inert surfaces and with large bond gaps, it offers great performance at low cure temperatures (< 15C / < 60F).
LOCTITE SF 7649 can be either sprayed or brushed onto one or both mating surfaces. For smaller gaps, it is only necessary to apply the accelerator to one surface. Pourous surfaces my require two treatments of activator.
Allow the solvent carrier of the activator to evaporate off completely so that the parts are dry to the touch. The accelerator has an on-part life of 30 days. Within that window of time, the anaerobic can be applied normally.